MOTS-C 20mg Peptide

MOTS-c is a short peptide encoded in the mitochondrial genome, one of a larger group known as mitochondrial-derived peptides, or MDPs. Recent research has established the MDPs as bioactive hormones with real jobs in mitochondrial communication and energy regulation. They were taken at first to be a mitochondrial matter alone; it has since emerged that many are active in the cell nucleus and that some reach the bloodstream and act systemically. MOTS-c is among the more recently identified of them, with reported roles in metabolism, weight regulation, exercise capacity, longevity and in the processes that lead to disease states such as osteoporosis. It has been found in the nucleus of cells and in the general circulation alike, which is what qualifies it as a genuine natural hormone.

MOTS-c is a 16 amino acid peptide encoded not in the nuclear genome but in the mitochondrial one, within the MT-RNR1 gene that also encodes the 12S ribosomal RNA. That origin is the most distinctive thing about it. Mitochondria were long assumed to encode only the thirteen respiratory chain subunits, and the identification of short open reading frames producing biologically active peptides established a class of molecules, the mitochondrial-derived peptides, of which MOTS-c is the most studied.

Functionally it is described as a retrograde signal: information travelling from mitochondrion to nucleus rather than the other direction. The original characterisation reported that MOTS-c targets the folate cycle and its tetrahydrofolate-dependent purine biosynthesis pathway, and that inhibition of that pathway leads to accumulation of AICAR, an endogenous activator of AMP-activated protein kinase. Activation of AMPK then produces the metabolic effects observed.

That indirect route matters for interpreting the literature. MOTS-c is not described as an AMPK ligand. It acts upstream, on a metabolic pathway whose intermediate happens to be an AMPK activator, which is a less direct mechanism than a receptor agonist and correspondingly harder to attribute cleanly. Later work has also reported nuclear translocation under metabolic stress and regulation of nuclear gene expression, which describes a second and distinct mode of action.

In mice, MOTS-c reverses age-dependent insulin resistance in muscle and so improves how much glucose the muscle takes up. The route is an improved skeletal muscle response to AMPK activation, which in turn raises the expression of glucose transporters[1]. That activation does not run through the insulin pathway, which makes it an alternative way of driving glucose into muscle where insulin is ineffective.

Mice with low estrogen levels put on fat mass and their adipose tissue stops working normally. Supplementing them with MOTS-c improves brown fat function and reduces how much adipose tissue accumulates. The peptide also appears to head off the adipose dysfunction and inflammation that typically run ahead of insulin resistance[2].

At least part of that influence on fat metabolism is mediated by AMPK activation. MOTS-c targets the methionine-folate cycle, raises AICAR levels and activates AMPK. Newer work suggests it can leave the mitochondria altogether and reach the nucleus, where it acts on nuclear gene expression: following metabolic stress it has been shown to regulate nuclear genes governing glucose restriction and antioxidant responses[3].

Evidence from mice makes MOTS-c an important regulator of sphingolipid, monoacylglycerol and dicarboxylate metabolism, particularly where obesity is present. Down-regulating those pathways while increasing beta-oxidation appears to be how it prevents fat accumulation[4].

The work has also produced a new hypothesis about fat deposition and insulin resistance. Where fat metabolism in the mitochondria is dysregulated, fat may go unoxidised; circulating fat then rises, and the body is forced to push insulin levels up in response[5].

Measurements taken across insulin sensitive and insulin resistant individuals found that the association with insulin sensitivity holds only in lean people. That has led to the suggestion that the peptide could be a useful way of monitoring lean pre-diabetic individuals, with a change in level acting as an early warning of insulin insensitivity to come[6].

MOTS-c appears to have a part in how osteoblasts synthesise type I collagen in bone. Work in osteoblast cell lines shows it regulating the TGF-beta/SMAD pathway, which is responsible for the health and survival of those cells[7].

Further research found it promoting the differentiation of bone marrow stem cells through that same TGF-beta/SMAD pathway, which leads directly to increased osteogenesis[8].

A specific change in the peptide has been linked to longevity in certain human populations, the Japanese among them. It substitutes a glutamate residue for the lysine normally found at position 14, occurs exclusively in people of Northeast Asian ancestry, and is thought to play a part in exceptional longevity[9].

Among patients undergoing coronary angiography, those with lower MOTS-c levels showed more endothelial cell dysfunction. Supplementing rats with the peptide improved endothelial function along with microvascular and epicardial blood vessel function[10].

At least three MDPs are thought to play a part in protecting cardiac cells against stress and inflammation[11].

The mitochondrial genome is small and was long thought to encode only thirteen proteins, all subunits of the respiratory chain, plus the transfer and ribosomal RNAs needed to make them. MOTS-c does not fit that description. It is encoded within a short open reading frame that overlaps the 12S ribosomal RNA gene, and it acts outside the mitochondrion.

This makes it part of a class rather than a curiosity. Humanin, also in this catalogue, was the first mitochondrial-derived peptide identified, and MOTS-c is the most studied of those that followed. The class matters conceptually because it establishes signalling from mitochondrion to nucleus and to the wider organism, rather than the nucleus-directs-mitochondrion relationship previously assumed.

The name records its origin: mitochondrial open reading frame of the 12S rRNA type-c.

MOTS-c is frequently described as an AMPK activator, which is a useful shorthand but not what the original work reported. The described sequence is that MOTS-c targets the folate cycle and its tetrahydrofolate-dependent purine biosynthesis pathway; inhibiting that pathway causes AICAR to accumulate; and AICAR is an endogenous AMPK activator.

The distinction is not pedantic. A molecule that binds and activates a kinase has a mechanism that can be tested directly. A molecule that perturbs a metabolic pathway whose intermediate activates a kinase has effects contingent on the state of that pathway, which will vary with cell type, nutrient availability and folate status.

The later reports of nuclear translocation under metabolic stress describe a second mode of action that is not obviously connected to the first. Both are published; neither has been shown to account for the full range of reported effects.

Much of the interest in MOTS-c comes from reports that circulating concentrations rise with exercise and decline with age, which has led to it being described as an exercise mimetic. Those are associations, and the direction of causation is not established by them.

A peptide whose concentration rises during exercise may be mediating a benefit of exercise, may be a marker of a process that mediates it, or may be responding to metabolic stress without contributing to the adaptation. The mouse intervention studies address this more directly than the correlational human data do, and they remain animal work.

The human data available so far are observational, including the association study in dialysis patients. There is no approved product and no interventional human trial of consequence. Material supplied for research is for in-vitro laboratory use only.

MOTS-c contains two methionines and two tyrosines, making it more oxidation-prone than most peptides of similar length. Methionine oxidation adds 16 daltons per residue, so partially oxidised species are a realistic related substance and appear as a series rather than a single satellite peak.

That composition makes storage conditions and buffer oxygenation more consequential here than for simpler sequences, and it makes the analytical method behind a purity figure worth reading, since a method that does not resolve oxidised forms will report them as parent.